Quantcast
Last updated on April 23, 2014 at 12:31 EDT

Latest Merrimack Pharmaceuticals Inc. Stories

2011-01-25 02:00:00

CAMBRIDGE, Mass., Jan. 25, 2011 /PRNewswire/ -- Michael Porter, Ph.D., has joined the board of directors of Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and development of novel treatments for cancer. (Photo: http://photos.prnewswire.com/prnh/20110125/NE34069 ) Professor Porter, the Bishop William Lawrence University Professor at Harvard Business School, is recognized as a leading authority on competitive strategy, the competitiveness...

2011-01-19 06:00:00

CAMBRIDGE, Mass., Jan. 19, 2011 /PRNewswire/ -- On February 1, 2011, the Massachusetts Institute of Technology (MIT) Department of Biological Engineering, Center for Biomedical Innovation, and Engineering Systems Division will host the Innovation in Healthcare Symposium: Systems Thinking from Discovery to Delivery at MIT's Kresge Auditorium. The day-long event, sponsored by Merrimack Pharmaceuticals, will be a forum to stimulate new ways of thinking about and addressing today's greatest...

2010-12-22 00:01:33

Robert Mulroy, President and Chief Executive Officer of Merrimack Pharmaceuticals, will provide a company overview at the 29th Annual JP Morgan Healthcare Conference in San Fransisco, California CAMBRIDGE, Mass. (Vocus/PRWEB) December 21, 2010 Merrimack Pharmaceuticals today announced that it will present at the 29th Annual JP Morgan Healthcare Conference in San Francisco. Robert Mulroy, President and Chief Executive Officer, will provide a company overview at 9:00am PST, Monday, January...

2010-12-10 00:00:58

MM-111 first-in-human phase 1/ 2 and pharmacologic study in patients with advanced refractory HER2-Positive (HER2+) cancers. MM-302 pre-clinical safety and activity study of anthracycline delivery to HER2-Positive (HER2+) tumors. Cambridge, MA (Vocus/PRWEB) December 08, 2010 Merrimack Pharmaceuticals, Inc. announced today that it will present MM-111 Phase 1 clinical data at the 33rd Annual San Antonio Breast Cancer Symposium, as well as pre-clinical data on MM-302, a HER2+ tumor...

2010-11-23 00:01:10

Robert Mulroy, President and Chief Executive Officer, will provide a company overview at the Piper Jaffray 22nd Annual Health Care Conference. (Vocus/PRWEB) November 22, 2010 Merrimack Pharmaceuticals today announced that it will present at the Piper Jaffray 22nd Annual Health Care Conference in New York City, New York. Robert Mulroy, President and Chief Executive Officer, will provide a company overview at 3:30pm, EST, Tuesday, November 30, 2010 at the New York Palace Hotel. About...

2010-11-08 14:00:00

CAMBRIDGE, Mass., Nov. 8, 2010 /PRNewswire/ -- Merrimack Pharmaceuticals was awarded $2.44 million to support research on 10 of its cancer programs through the Qualifying Therapeutic Discovery Project, a grant program created as part of the Patient Protection and Affordable Care Act of 2010 to advance research in areas of unmet medical need. Merrimack received one of the largest grants awarded to the companies in Massachusetts and was one of the top ten recipients across the United...

2010-09-13 10:22:00

CAMBRIDGE, Mass., Sept. 13 /PRNewswire/ -- Merrimack Pharmaceuticals today announced that it will present at the Stifel Nicolaus 2010 Healthcare Conference in Boston. William Sullivan, Vice President of Finance, will provide a company overview at 11:30am, EDT, Friday, September 17, 2010 at the Four Seasons Hotel in Boston, Massachusetts. (Logo: http://photos.prnewswire.com/prnh/20100913/NE63515LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20100913/NE63515LOGO ) About Merrimack...

2010-07-22 06:00:00

CAMBRIDGE, Mass., July 22 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients. MM-121, Merrimack's lead oncology therapeutic candidate, is an antibody designed to block signaling of ErbB3. ErbB3 is a key mediator of the ErbB pathway, a pathway...

2010-06-17 15:02:00

CAMBRIDGE, Mass., June 17 /PRNewswire/ -- Melissa Kemp, Ph.D., was named the winner of the third annual Council for Systems Biology in Boston (CSB2) Award, sponsored by Merrimack Pharmaceuticals, Inc. The award was presented this morning during the CSB2 2010 International Conference on Systems Biology of Human Disease. "Sponsoring the CSB2 Award is a natural fit for Merrimack, as our company mission is to use systems biology techniques to understand a disease mechanism and then discover...

2010-06-03 06:00:00

CAMBRIDGE, Mass., June 3 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the design of their Phase 1/2 trial investigating the safety and tolerability of MM-111 in HER2 positive cancer patients will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 4-8, 2010, in Chicago, Illinois. MM-111 is a bi-specific antibody designed to specifically inhibit ErbB3 (HER3) signaling in ErbB2 (HER2) over expressing cancer cells....